MED18

Summary

MED18 (mediator complex subunit 18, HGNC:25944) is a protein-coding gene on chromosome 1p35.3, encoding Mediator of RNA polymerase II transcription subunit 18 (Q9BUE0). Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. It is a selective cancer dependency (DepMap: 89.4% of cell lines).

MED18 is a component of the Mediator complex, which is a coactivator for DNA-binding factors that activate transcription via RNA polymerase II (Sato et al., 2003 [PubMed 12584197]).

Source: NCBI Gene 54797 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 33 total
• Cancer dependency (DepMap): dependent in 89.4% of screened cell lines
• MANE Select transcript: NM_017638

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25944
Approved symbol	MED18
Name	mediator complex subunit 18
Location	1p35.3
Locus type	gene with protein product
Status	Approved
Aliases	FLJ20045, p28b, SRB5
Ensembl gene	ENSG00000130772
Ensembl biotype	protein_coding
OMIM	612384
Entrez	54797

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 3 protein_coding_CDS_not_defined, 2 protein_coding

ENST00000373842, ENST00000398997, ENST00000474683, ENST00000475655, ENST00000479574

RefSeq mRNA: 2 — MANE Select: NM_017638 NM_001127350, NM_017638

CCDS: CCDS322

Canonical transcript exons

ENST00000373842 — 3 exons

Exon	Start	End
ENSE00001207949	28329040	28329180
ENSE00001866153	28334417	28335965
ENSE00003557417	28330597	28330735

Expression profiles

Bgee: expression breadth ubiquitous, 134 present calls, max score 87.11.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 10.6066 / max 94.0650, expressed in 1783 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
1789	10.6066	1783

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
mucosa of transverse colon	UBERON:0004991	87.11	gold quality
islet of Langerhans	UBERON:0000006	86.77	gold quality
stromal cell of endometrium	CL:0002255	85.41	gold quality
lymph node	UBERON:0000029	84.16	gold quality
blood	UBERON:0000178	84.00	gold quality
rectum	UBERON:0001052	83.87	gold quality
granulocyte	CL:0000094	82.84	gold quality
skeletal muscle tissue	UBERON:0001134	82.72	gold quality
duodenum	UBERON:0002114	82.64	gold quality
muscle tissue	UBERON:0002385	82.43	gold quality
vermiform appendix	UBERON:0001154	82.00	gold quality
liver	UBERON:0002107	81.90	gold quality
hindlimb stylopod muscle	UBERON:0004252	81.88	gold quality
leukocyte	CL:0000738	81.87	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	81.75	gold quality
monocyte	CL:0000576	81.56	gold quality
muscle of leg	UBERON:0001383	81.52	gold quality
gastrocnemius	UBERON:0001388	81.32	gold quality
placenta	UBERON:0001987	81.14	gold quality
transverse colon	UBERON:0001157	80.83	gold quality
tonsil	UBERON:0002372	80.77	gold quality
right adrenal gland	UBERON:0001233	80.73	gold quality
right adrenal gland cortex	UBERON:0035827	80.65	gold quality
right lobe of liver	UBERON:0001114	80.58	gold quality
smooth muscle tissue	UBERON:0001135	80.32	gold quality
esophagus mucosa	UBERON:0002469	80.12	gold quality
small intestine	UBERON:0002108	80.04	gold quality
pancreas	UBERON:0001264	79.87	gold quality
small intestine Peyer’s patch	UBERON:0003454	79.72	gold quality
bone marrow	UBERON:0002371	79.53	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.65

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

49 targeting MED18, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-1229-3P	99.97	66.49	906
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-221-5P	99.86	65.45	1052
HSA-MIR-8073	99.86	65.21	1118
HSA-MIR-6515-3P	99.82	68.19	1933
HSA-MIR-556-3P	99.74	68.75	1203
HSA-MIR-6745	99.74	65.33	1321
HSA-MIR-6134	99.63	65.68	1537
HSA-MIR-766-3P	99.47	65.24	1811
HSA-MIR-504-3P	99.30	67.18	1745
HSA-MIR-4784	99.15	67.41	1733
HSA-MIR-661	99.09	65.94	2062
HSA-MIR-4695-5P	99.06	64.87	1151
HSA-MIR-3926	98.95	69.26	1438
HSA-MIR-3150B-3P	98.81	67.21	1728
HSA-MIR-7113-3P	98.75	65.71	1120
HSA-MIR-4763-5P	98.75	63.89	854
HSA-MIR-548S	98.50	67.17	1213
HSA-MIR-6878-5P	98.49	67.91	2142
HSA-MIR-5089-5P	98.45	66.06	1388

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 89.4% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 2)

• A novel transcriptional repression mechanism of hMED18 mediated by hCDK8 and further a novel positive role of free CDK/cyclin module in transcriptional activation is described. (PMID:24840924)
• Long non-coding RNA SNHG3 promotes progression of gastric cancer by regulating neighboring MED18 gene methylation. (PMID:31534128)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	med18	ENSDARG00000041237
mus_musculus	Med18	ENSMUSG00000066042
rattus_norvegicus	Med18	ENSRNOG00000067073
drosophila_melanogaster	MED18	FBGN0026873
caenorhabditis_elegans	mdt-18	WBGENE00007018

Protein

Protein identifiers

Mediator of RNA polymerase II transcription subunit 18 — Q9BUE0 (reviewed: Q9BUE0)

Alternative names: Mediator complex subunit 18, p28b

All UniProt accessions (1): Q9BUE0

UniProt curated annotations — full annotation on UniProt →

Function. Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional preinitiation complex with RNA polymerase II and the general transcription factors.

Subunit / interactions. Component of the Mediator complex, which is composed of MED1, MED4, MED6, MED7, MED8, MED9, MED10, MED11, MED12, MED13, MED13L, MED14, MED15, MED16, MED17, MED18, MED19, MED20, MED21, MED22, MED23, MED24, MED25, MED26, MED27, MED29, MED30, MED31, CCNC, CDK8 and CDC2L6/CDK11. The MED12, MED13, CCNC and CDK8 subunits form a distinct module termed the CDK8 module. Mediator containing the CDK8 module is less active than Mediator lacking this module in supporting transcriptional activation. Individual preparations of the Mediator complex lacking one or more distinct subunits have been variously termed ARC, CRSP, DRIP, PC2, SMCC and TRAP.

Subcellular location. Nucleus.

Similarity. Belongs to the Mediator complex subunit 18 family.

RefSeq proteins (2): NP_001120822, NP_060108* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR019095	Mediator_Med18	Family

Pfam: PF09637

UniProt features (17 total): strand 10, helix 3, chain 1, modified residue 1, turn 1, sequence conflict 1

Structure

Experimental structures (PDB)

11 structures.

PDB	Method	Resolution (Å)
7EMF	ELECTRON MICROSCOPY	3.5
8TRH	ELECTRON MICROSCOPY	3.7
7ENA	ELECTRON MICROSCOPY	4.07
7ENC	ELECTRON MICROSCOPY	4.13
8GXS	ELECTRON MICROSCOPY	4.16
7ENJ	ELECTRON MICROSCOPY	4.4
7NVR	ELECTRON MICROSCOPY	4.5
8T9D	ELECTRON MICROSCOPY	4.66
7LBM	ELECTRON MICROSCOPY	4.8
8GXQ	ELECTRON MICROSCOPY	5.04
8TQW	ELECTRON MICROSCOPY	8.2

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BUE0-F1	90.12	0.78

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 66

Function

Pathways and Gene Ontology

Reactome pathways

12 pathways

ID	Pathway
R-HSA-1989781	PPARA activates gene expression
R-HSA-381340	Transcriptional regulation of white adipocyte differentiation
R-HSA-9833110	RSV-host interactions
R-HSA-1266738	Developmental Biology
R-HSA-1430728	Metabolism
R-HSA-1643685	Disease
R-HSA-400206	Regulation of lipid metabolism by PPARalpha
R-HSA-556833	Metabolism of lipids
R-HSA-5663205	Infectious disease
R-HSA-9820952	Respiratory Syncytial Virus Infection Pathway
R-HSA-9824446	Viral Infection Pathways
R-HSA-9843745	Adipogenesis

MSigDB gene sets: 119 (showing top): REACTOME_TRANSCRIPTIONAL_REGULATION_OF_WHITE_ADIPOCYTE_DIFFERENTIATION, GOBP_POSITIVE_REGULATION_OF_DNA_TEMPLATED_TRANSCRIPTION_INITIATION, MODULE_205, GOBP_REGULATION_OF_DNA_TEMPLATED_TRANSCRIPTION_INITIATION, TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_10D_UP, GOBP_DNA_TEMPLATED_TRANSCRIPTION_INITIATION, GOBP_TRANSCRIPTION_INITIATION_AT_RNA_POLYMERASE_II_PROMOTER, LASTOWSKA_NEUROBLASTOMA_COPY_NUMBER_DN, GOBP_PROTEIN_DNA_COMPLEX_ORGANIZATION, GOBP_POSITIVE_REGULATION_OF_DNA_TEMPLATED_TRANSCRIPTION_ELONGATION, GOBP_REGULATION_OF_DNA_TEMPLATED_TRANSCRIPTION_ELONGATION, PARENT_MTOR_SIGNALING_UP, GOCC_RNA_POLYMERASE_II_TRANSCRIPTION_REGULATOR_COMPLEX, GOCC_TRANSCRIPTION_REGULATOR_COMPLEX, MARSON_BOUND_BY_E2F4_UNSTIMULATED

GO Biological Process (4): positive regulation of transcription elongation by RNA polymerase II (GO:0032968), RNA polymerase II preinitiation complex assembly (GO:0051123), positive regulation of transcription initiation by RNA polymerase II (GO:0060261), regulation of transcription by RNA polymerase II (GO:0006357)

GO Molecular Function (2): transcription coregulator activity (GO:0003712), protein binding (GO:0005515)

GO Cellular Component (4): nucleus (GO:0005634), nucleoplasm (GO:0005654), mediator complex (GO:0016592), core mediator complex (GO:0070847)

Reactome top-level categories

Rollup of top-9 pathways:

Category	Pathways
Regulation of lipid metabolism by PPARalpha	1
Adipogenesis	1
Respiratory Syncytial Virus Infection Pathway	1
Metabolism of lipids	1
Metabolism	1
Disease	1
Viral Infection Pathways	1
Infectious disease	1
Developmental Biology	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
positive regulation of transcription by RNA polymerase II	2
transcription initiation at RNA polymerase II promoter	2
transcription elongation by RNA polymerase II	1
positive regulation of DNA-templated transcription, elongation	1
regulation of transcription elongation by RNA polymerase II	1
transcription preinitiation complex assembly	1
regulation of transcription initiation by RNA polymerase II	1
positive regulation of DNA-templated transcription initiation	1
regulation of DNA-templated transcription	1
transcription by RNA polymerase II	1
transcription regulator activity	1
binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cellular anatomical structure	1
core mediator complex	1
nuclear protein-containing complex	1
RNA polymerase II transcription regulator complex	1

Protein interactions and networks

STRING

1064 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MED18	MED20	Q9H944	999
MED18	MED11	Q9P086	998
MED18	MED8	Q96G25	996
MED18	MED6	O75586	995
MED18	MED22	Q15528	991
MED18	MED29	Q9NX70	979
MED18	MED19	A0JLT2	977
MED18	MED10	Q9BTT4	959
MED18	MED17	Q9NVC6	950
MED18	MED30	Q96HR3	931
MED18	MED14	O60244	931
MED18	CDK8	P49336	913
MED18	MED16	Q9Y2X0	888
MED18	MED15	Q96RN5	884
MED18	MED21	Q13503	873

IntAct

150 interactions, top by confidence:

A	B	Type	Score
MED20	MED18	psi-mi:“MI:0915”(physical association)	0.960
MED18	MED20	psi-mi:“MI:0915”(physical association)	0.960
MED10	MED19	psi-mi:“MI:0914”(association)	0.910
MED10	MED19	psi-mi:“MI:0915”(physical association)	0.910
MED4	MED19	psi-mi:“MI:2364”(proximity)	0.900
MED4	MED19	psi-mi:“MI:0914”(association)	0.900
MED29	MED19	psi-mi:“MI:0914”(association)	0.890
MED29	MED18	psi-mi:“MI:0914”(association)	0.890
MED29	MED18	psi-mi:“MI:0915”(physical association)	0.890
MED21	MED19	psi-mi:“MI:0914”(association)	0.880

BioGRID (289): MED18 (Two-hybrid), MED18 (Two-hybrid), TRIM39 (Two-hybrid), HOMEZ (Two-hybrid), MED18 (Affinity Capture-MS), MED18 (Affinity Capture-MS), MED18 (Affinity Capture-MS), MED1 (Co-fractionation), MED11 (Co-fractionation), MED12 (Co-fractionation), MED14 (Co-fractionation), MED15 (Co-fractionation), MED16 (Co-fractionation), MED17 (Co-fractionation), MED18 (Co-fractionation)

ESM2 similar proteins: A1CE73, A1CGW7, A1CLT5, A1CQ63, A1D327, A1DM82, A2Q9L8, A2RBB7, A4D9J5, A4RI88, G0RYC6, G0S0E7, G0S8H7, G0S9A7, O14198, P34162, P91641, Q0CL68, Q0VCD4, Q17IN5, Q1E065, Q28GE1, Q2H4N1, Q2KG01, Q2UMB8, Q4WNC6, Q54MR3, Q5B128, Q5BE03, Q5KEQ1, Q61D43, Q6BXL9, Q6CAY6, Q6CDK1, Q6DD39, Q6DRD4, Q6FSU0, Q755F7, Q75EI4, Q7QGX9

Diamond homologs: Q0VCD4, Q17IN5, Q28GE1, Q6DD39, Q7QGX9, Q7T3H7, Q966M5, Q9BUE0, Q9CZ82, Q9XZT1, Q61D43

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
MED18	“form complex”	“Core mediator complex”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 68 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Respiratory Syncytial Virus Infection Pathway	25	98.5×	5e-44
RSV-host interactions	25	78.2×	2e-41
Adipogenesis	25	78.2×	2e-41
Regulation of lipid metabolism by PPARalpha	25	70.5×	4e-40
Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes	16	69.0×	8e-25
Transcriptional regulation of white adipocyte differentiation	25	64.9×	3e-39
Epigenetic regulation of gene expression by MLL3 and MLL4 complexes	16	63.0×	3e-24
Epigenetic regulation by WDR5-containing histone modifying complexes	16	49.4×	2e-22

GO biological processes:

GO term	Partners	Fold	FDR
positive regulation of transcription elongation by RNA polymerase II	21	107.1×	1e-36
positive regulation of transcription initiation by RNA polymerase II	22	101.3×	1e-37
RNA polymerase II preinitiation complex assembly	21	96.7×	9e-36
transcription initiation at RNA polymerase II promoter	8	50.8×	2e-10
somatic stem cell population maintenance	11	46.2×	4e-14
protein ubiquitination	12	8.4×	8e-07
transcription by RNA polymerase II	7	8.4×	7e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

33 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	30
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

290 predictions. Top by Δscore:

Variant	Effect	Δscore
1:28329178:G:GT	donor_gain	1.0000
1:28330591:TTCCA:T	acceptor_loss	1.0000
1:28330592:TCCA:T	acceptor_loss	1.0000
1:28330593:CCA:C	acceptor_loss	1.0000
1:28330594:CA:C	acceptor_loss	1.0000
1:28330595:AGGTA:A	acceptor_loss	1.0000
1:28330596:G:GA	acceptor_loss	1.0000
1:28330731:GCAGG:G	donor_gain	1.0000
1:28330732:CAGG:C	donor_gain	1.0000
1:28330732:CAGGG:C	donor_loss	1.0000
1:28330734:GG:G	donor_gain	1.0000
1:28330735:GG:G	donor_gain	1.0000
1:28330736:G:GG	donor_gain	1.0000
1:28330736:GTA:G	donor_loss	1.0000
1:28330737:T:A	donor_loss	1.0000
1:28334416:GGA:G	acceptor_gain	1.0000
1:28334416:GGAA:G	acceptor_gain	1.0000
1:28329177:GGAG:G	donor_gain	0.9900
1:28329178:G:T	donor_gain	0.9900
1:28329232:G:GT	donor_gain	0.9900
1:28330596:GGT:G	acceptor_gain	0.9900
1:28330596:GGTAT:G	acceptor_gain	0.9900
1:28330719:G:GT	donor_gain	0.9900
1:28330733:AGG:A	donor_gain	0.9900
1:28330734:GGG:G	donor_gain	0.9900
1:28334412:TTCA:T	acceptor_loss	0.9900
1:28334415:A:AG	acceptor_gain	0.9900
1:28334415:AG:A	acceptor_gain	0.9900
1:28334416:G:GG	acceptor_gain	0.9900
1:28334416:GG:G	acceptor_gain	0.9900

AlphaMissense

1400 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:28330735:G:A	G25R	1.000
1:28330735:G:C	G25R	1.000
1:28334459:T:C	L39P	1.000
1:28334921:T:C	L193P	1.000
1:28334417:G:A	G25E	0.999
1:28334423:T:A	V27D	0.999
1:28334455:C:A	R38S	0.999
1:28334459:T:A	L39H	0.999
1:28334464:G:C	G41R	0.999
1:28334465:G:A	G41D	0.999
1:28334471:G:A	C43Y	0.999
1:28334597:T:C	L85P	0.999
1:28334600:G:C	R86P	0.999
1:28334602:T:G	Y87D	0.999
1:28334651:G:C	R103P	0.999
1:28334740:G:A	G133R	0.999
1:28334740:G:C	G133R	0.999
1:28334741:G:A	G133E	0.999
1:28334933:T:A	V197D	0.999
1:28334447:T:C	L35P	0.998
1:28334456:G:C	R38P	0.998
1:28334459:T:G	L39R	0.998
1:28334472:T:G	C43W	0.998
1:28334558:C:A	A72D	0.998
1:28334609:G:A	G89E	0.998
1:28334696:T:C	L118S	0.998
1:28334710:T:C	F123L	0.998
1:28334711:T:C	F123S	0.998
1:28334712:C:A	F123L	0.998
1:28334712:C:G	F123L	0.998

dbSNP variants (sampled 300 via entrez): RS1000090415 (1:28335913 T>A), RS1000273693 (1:28331028 T>C), RS1001191827 (1:28329992 G>A,C), RS1001328743 (1:28330236 T>C), RS1001339585 (1:28336375 T>C), RS1001623422 (1:28330198 C>T), RS1001931813 (1:28331749 ATT>A,AT,ATTT,ATTTT), RS1002221418 (1:28328995 G>A,C), RS1002342080 (1:28335273 C>G), RS1002374693 (1:28335499 C>G,T), RS1002596809 (1:28328837 C>G), RS1003209061 (1:28327509 C>A,G), RS1003347317 (1:28333628 G>A), RS1003397827 (1:28333726 G>C), RS1003649575 (1:28327831 C>T)

Disease associations

OMIM: gene MIM:612384 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST004250_24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL)	3.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0007965	response to combination chemotherapy

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

29 total (human), top 29 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases abundance, increases expression, increases stability, decreases expression	5
Arsenic	increases abundance, increases methylation, decreases expression	2
Benzo(a)pyrene	affects methylation, increases expression	2
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
bisphenol F	increases expression, affects cotreatment	1
urushiol	decreases expression	1
bisphenol A	affects cotreatment, increases expression	1
ferrous chloride	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
corosolic acid	increases expression	1
monomethylarsonous acid	decreases expression	1
bisphenol S	affects cotreatment, increases expression	1
Dexamethasone	affects cotreatment, increases expression	1
Diethylhexyl Phthalate	increases expression	1
Estradiol	affects expression	1
Indomethacin	affects cotreatment, increases expression	1
Rotenone	decreases expression	1
Silicon Dioxide	decreases expression	1
Dronabinol	decreases expression	1
Thimerosal	decreases expression	1
Thiram	decreases expression	1
Tretinoin	increases expression	1
Urethane	increases expression	1
1-Methyl-3-isobutylxanthine	affects cotreatment, increases expression	1
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	1
Metribolone	affects splicing	1
Cadmium Chloride	decreases expression	1
Lactic Acid	decreases expression	1
Acrylamide	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.